Robert Kirby

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 586 citations

Medicine, Oncology, Pharmacology +11

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 540 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes

Joanne L. Blum, Michael A. Savin, Gerald M. Edelman et al. · Clinical Breast Cancer · 2007 · 178 citations

Medicine, Oncology, Pharmacology +16

Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.

Sarah E. Jones, M W Schottstaedt, Lewis A. Duncan et al. · Journal of Clinical Oncology · 1996 · 52 citations

Medicine, Oncology, Pharmacology +16

Low Proliferative Rate of Invasive Node-Negative Breast Cancer Predicts for a Favorable Outcome: A Prospective Evaluation of 669 Patients

Stephen E. Jones, Gary M. Clark, Sherry Koleszar et al. · Clinical Breast Cancer · 2001 · 22 citations

Medicine, Oncology, Breast Oncology +9